TP53 and B-cell chronic lymphocytic leukemia: Thus, venetoclax was soon approved by the FDA as a treatment option for CLL patients harboring deletion 17p and by the EMA for CLL patients with del17p or TP53 mutations, who cannot use BTKi due to relapse or unsuitability and patients who do not present with the mutations and fail both chemoimmunotherapy and BTKi.